Formycon AG (FYB) Earnings Call Transcripts

Formycon AG's Latest Earnings Call - Q1 FY2026

In Q1 2026, Formycon AG reported significant revenue growth, more than doubling revenues compared to Q1 2025, driven by strong performance in their biosimilar products, particularly FYB202 and FYB206. The company achieved an adjusted EBITDA loss of EUR 3.6 million, an improvement from a loss of EUR 11.8 million in the prior year. Management maintained their full-year guidance, indicating confidence in continued growth and profitability as they expand their product pipeline and geographic reach.

Reported metrics

Guidance from management

Management maintained their full-year guidance, indicating that growth will be driven by FYB202 and FYB206, with expectations for continued positive contributions from these products throughout the year.

What management said

Was on the joint venture Q1 performance for Bioeq, so to say. And Nicolas, I think your interpretation is correct that we are assuming that this will swing into a positive performance for the subsequent quarters to come. It's a kind of regular not always matching inventory building and sales. So that's the typical behavior you see in some products. But nothing concerning. Okay. With that, Nicolas, are you fine with t...

Okay. Happy to start with the first one. So any further non-206 milestones, not foreseen for now. Of course, that gives us also the flexibility for an opportunity -- upside opportunity if we strike deals, but we need the flexibility not to be forced into synergies because we want -- we need that to deliver our guidance. So we're clear from today's point of view, guidance is not having any non-206reated milestones.

What analysts pressed on

Analysts raised concerns regarding the joint venture's performance and the potential delays in achieving milestones for FYB206. There were also questions about the impact of competitive pressures in the U.S. market and the timeline for product launches.

Main topics on the call

• Revenue Growth Acceleration — Formycon reported revenues that more than doubled compared to Q1 2025, reflecting strong operational momentum. Management stated, 'Revenues are on track and show a significant step-up versus Q1 2025.'
• Launch of New Products — The successful launch of FYB203, a biosimilar to Eylea, in Europe is a key milestone for Formycon. 'On 15th of May, we successfully launched our third pipeline product, CYP203, a biosimilar to Eylea in Europe,' managemen...
• Cost Management and EBITDA Improvement — Formycon's adjusted EBITDA improved significantly, with a loss of EUR 3.6 million compared to EUR 11.8 million in Q1 2025. This was attributed to stable costs and reduced R&D expenses, indicating effective cost managemen...
• Geographic Diversification Strategy — Management emphasized the importance of geographic diversification, stating, 'Formycon deliberately expands into high-growth emerging regions.' This strategy aims to mitigate risks and enhance patient access.

Read the full Formycon AG transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 8 Formycon AG earnings call transcripts on record, spanning November 28, 2024 to August 12, 2026. Based on this history, Formycon AG reports quarterly. The most recent call on file is dated August 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

FYB

Exchange

XTRA

Country

DE

Sector

Health Care

Industry

Biotechnology

Calls on record

8

First call

November 28, 2024

Most recent

August 12, 2026

Reporting cadence

quarterly